{
  "id": "5e44cf61f5547e6e27000001",
  "type": "factoid",
  "question": "What is targeted by Pexidartinib?",
  "ideal_answer": "Pexidartinib is a selective tyrosine kinase inhibitor against CSF1R.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28536100",
    "http://www.ncbi.nlm.nih.gov/pubmed/31229240",
    "http://www.ncbi.nlm.nih.gov/pubmed/31258629",
    "http://www.ncbi.nlm.nih.gov/pubmed/32440095",
    "http://www.ncbi.nlm.nih.gov/pubmed/32297819",
    "http://www.ncbi.nlm.nih.gov/pubmed/31862477",
    "http://www.ncbi.nlm.nih.gov/pubmed/30825104",
    "http://www.ncbi.nlm.nih.gov/pubmed/31602563",
    "http://www.ncbi.nlm.nih.gov/pubmed/30926949",
    "http://www.ncbi.nlm.nih.gov/pubmed/32617868",
    "http://www.ncbi.nlm.nih.gov/pubmed/31213500",
    "http://www.ncbi.nlm.nih.gov/pubmed/31240240",
    "http://www.ncbi.nlm.nih.gov/pubmed/31848580",
    "http://www.ncbi.nlm.nih.gov/pubmed/32306101",
    "http://www.ncbi.nlm.nih.gov/pubmed/32943455",
    "http://www.ncbi.nlm.nih.gov/pubmed/30002809"
  ],
  "snippets": [
    {
      "text": "Elucidation of the importance of the colony-stimulating factor (CSF1)/CSF1 receptor (CSF1R) pathway in the pathogenesis of this disease has created significant interest in targeting this pathway as a novel TGCT treatment approach. Pexidartinib, a selective tyrosine kinase inhibitor against CSF1R, showed an 83% disease control rate (52% with partial response and 31% with stable disease) in a recent phase 1 study of patients with TGCT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30002809",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We show that M-CSFR inhibition using the CSF-1R kinase inhibitor PLX3397 (pexidartinib) effectively reduced numbers of TAMs, circulating nonclassical monocytes, as well as amount of neoangiogenesis and ascites in mesothelioma mouse models, but did not improve survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28536100",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib (TURALIO\u2122) is an orally administered small molecule tyrosine kinase inhibitor with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto-oncogene receptor tyrosine kinase (KIT) and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation (FLT3-ITD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31602563",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ODS: This was an investigator-initiated, phase I, dose escalation study of the MEK inhibitor binimetinib combined with pexidartinib, a potent inhibitor of CSF1R, KIT, and FLT3, in patients with advanced or metastatic GIST who progressed on imatinib. The",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31213500",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib, an oral inhibitor of tyrosine kinases including colony stimulating factor 1 receptor (CSF-1R), KIT, and FLT3, is FDA approved in adults with tenosynovial giant cell tumor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32943455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib is a CSF1R antagonist that is prescribed for the treatment of tenosynovial giant cell tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31862477",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase inhibitor, has strong selectivity against colony-stimulating factor 1 receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30825104",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Pexidartinib (PLX3397) is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor under clinical evaluation for potential CNS tumor treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32306101",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tumors. Pexidartinib, an oral inhibitor of tyrosine kinases including colony stimulating factor 1 receptor (CSF-1R), KIT, and FLT3, is FDA approved in adults with tenosynovial giant cell tumor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32943455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib (TURALIO\u2122) is an orally administered small molecule tyrosine kinase inhibitor with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto-oncogene receptor tyrosine kinase (KIT) and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation (FLT3-ITD). In August",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31602563",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin's lymphoma, and glioblastoma. Here, we",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31240240",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30825104",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Purpose: To evaluate the safety, recommended phase\u2009II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor\u20091 (CSF-1R) inhibitor, in combination with weekly paclitaxel in patients with advanced solid tumors",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31258629",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib (PLX3397) is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor under clinical evaluation for potential CNS tumor treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32306101",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32306101",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pexidartinib is an oral tyrosine kinase inhibitor with selective inhibition of colony-stimulating factor 1 receptor and is the first systemic therapy to show significant improvement in overall response rates when compared with placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32617868",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tor 1 (CSF1). Pexidartinib (Turalio\u2122) is a selective CSF1\u00a0R inhibitor, which was recently approved by the FDA for the trea",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32297819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "t approach. Pexidartinib, a selective tyrosine kinase inhibitor against CSF1R, showed an 83% disease control rate (52% with partial response and 31% with stable disease) in a recent phase 1 study of patient",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30002809",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib is an orally bioavailable and potent inhibitor of CSF-1R which is one of the most clinically used agents.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32440095",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32440095",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We aimed to evaluate pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT to provide them with a viable systemic treatment option, especially in cases that are not amenable to surgical resection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31229240",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30926949",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "To address the role of these cells in disease pathogenesis, we depleted microglia from R6/2 mice, a rapidly progressing model of Huntington's disease marked by behavioural impairment, mutant huntingtin (mHTT) accumulation, and early death, through colony-stimulating factor 1 receptor inhibition (CSF1Ri) with pexidartinib (PLX3397) for the duration of disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31848580",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "CSF1R"
}